Showing results (171-180 of 187) with videos related to

Sort By:
Pageof 19
International Journal of Clinical Oncology|December 16, 2019
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS studyToshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, et al.
Cancer Science|July 6, 2025
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction CancerAkihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi, et al.
The Oncologist|September 13, 2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyToshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, et al.
International Journal of Clinical Oncology|July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumTakahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumRyosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|August 28, 2024
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON studyYoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 1, 2022
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in JapanMasahiko Aoki, Shigenori Kadowaki, Naoki Takahashi, et al.
Frontiers in Oncology|July 2, 2021
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil TreatmentHiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, et al.
Cardiovascular Research|September 17, 2009
S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen speciesNoriko Takuwa, Sei-Ichiro Ohkura, Shin-Ichiro Takashima, et al.
Frontiers in Oncology|March 25, 2021
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)Keigo Chida, Daisuke Kotani, Toshikazu Moriwaki, et al.
Pageof 19